Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Aventis, PharmaNetics to co-market heparin

Executive Summary

In a five-year deal, Aventis Pharmaceuticals and PharmaNetics (drug evaluating technologies) will develop a therapeutic diagnostic test for use with Aventis's top-selling low-molecular-weight heparin Lovenox (enoxaparin sodium; also marketed outside the US as Clexane and Klexane).
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Therapeutic Drug Monitoring
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Marketing
    • R+D and Marketing-Licensing

Related Companies